EMA to evaluate Richter’s new drug teriparatide

Pharma

The European Medicines Agency (EMA) has accepted Hungarian drugmaker Gedeon Richter’s regulatory submission for the proposed biosimilar to Eli Lilly’s Forteo (teriparatide), according to a press release issued by the company today.

Biosimilar teriparatide was developed by Richter-Helm BioTec GmbH & Co. KG, based in Hamburg, and according to license agreements, the new drug will be launched under both Richter and STADA labels in geographical Europe once the patent of the original product has expired, the press release noted.

“Teriparatide is prescription only medicine used for the treatment of osteoporosis, leading to frequent bone fractures,” according to the press release. Richter added that Teriparatide is identical to the biologically active fragment of the human parathyroid hormone and replaces the natural hormone to stimulate bone formation.

Gedeon Richter Plc., a major player in the Central Eastern Europe pharmaceutical industry, had consolidated sales of approximately €1.1 billion ($1.5 bln), while its market capitalization amounted to €2.1 bln ($2.5 bln) in 2014, the company said.

ADVERTISEMENT

Consumer price levels below EU avg in 2020 Analysis

Consumer price levels below EU avg in 2020

Lawmakers approve 2022 budget Parliament

Lawmakers approve 2022 budget

Dentons rehires banking and finance partner Appointments

Dentons rehires banking and finance partner

Budapest launches revamped coupon card for visitors City

Budapest launches revamped coupon card for visitors

SUPPORT THE BUDAPEST BUSINESS JOURNAL

Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.